European Commission logo
English English
CORDIS - EU research results
CORDIS

PrDx - Advanced Software for Predicting the Immune Response During Drug Development

Project description

Innovative software for prediction of the vaccine immunogenic epitopes

The immunogenicity prediction tools, epitope prediction software (EIPS) and assays, are necessary for cost-effective and safe drug development. However, the precision and predictive power of the available EIPS are limited, with less than 10 % of the predicted immunogenic epitopes inducing an immune response. Danish Immunitrack has developed a next-generation EIPS with high accuracy and no false positives as a tool for streamlining drug and vaccine development. The software identifies immunogenic epitopes for a vaccine, points to the unwanted immunogenic properties of a developed drug, and guides treatment via the immune response assessment. The EU-funded ImmuniPrDx project will conduct certification activities and user tests for demonstration and validation, critical for user benefits.

Objective

>90% of drug and vaccine candidates fail during drug development, resulting in an average of €35M lost per drug for the pharma companies, and a slow and expensive drug development process. A major reason for failure is unwanted/lack of immune response of the drug/vaccine candidate. Thus, immunogenicity prediction tools, Epitope Prediction Software (EIPS) and assays, are important for cost-effective and safe drug development. However, available EIPS are over-predictive and limited: using the current gold standard EIPS netMHC, <10% of the predicted immunogenic epitopes induce an immune response. Immunitrack has developed a next generation EIPS - PrDx - that with high accuracy and no false positives far exceeds the performance of netMHC. PrDx, to be applied alone or in combination with our successfully commercialized immunogenicity assays, is a strong tool for streamlining drug and vaccine development, meeting user needs for multiple applications: i) identify immunogenic epitopes to be included in a vaccine; ii) identify unwanted immunogenic properties of a newly developed drug, and iii) guide treatment by assessing patient immune response. For commercialisation, PrDx must be shaped into a customer friendly format and meet regulatory demands; the goal of the Innovation project is to conduct activities related to certifications and requirements, and user tests for demonstration and validation, critical for PrDx awareness and knowledge of user benefits. Immunitrack will sell PrDx reports for drug/vaccine candidate immunogenicity screening and complementing immunogenicity assays, through direct and indirect sales with a predicted accumulated turnover of €56M 5 years post commercialization. Immunitrack has unique capacities confirmed by our 90 customers within PrDx’s target group, from Europe, US and Asia, including several top pharma companies.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

IMMUNITRACK APS
Net EU contribution
€ 50 000,00
Address
LERSO PARKALLE 42, 4TV
2100 KOBENHAVN
Denmark

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Danmark Hovedstaden Byen København
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00